Association of LAG-3 expression in circulating T cells and response to combination temozolomide (TMZ) and nivolumab (NIVO) in advanced neuroendocrine neoplasms (NENs): Results from an investigator-initiated phase 2 trial

This article has no abstract
Epistemonikos ID: cf1d515dbc5e9f3d3fd73b17a32a5edcf1f1300d
First added on: Feb 14, 2025